Mark Corrigan, M.D.

Dr. Corrigan was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine.

Before entering the healthcare industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department.

Dr. Corrigan served on the Board of Directors for Cubist Pharmaceuticals and of Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and served as chairman of EPIRUS Biopharmaceuticals’ Board.

Dr. Corrigan holds an M.D. degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.